FAP and pancreatic neoplasm: Although some side-effects like enhanced tumor hypoxia and Treg infiltration may arise with α-SMA targeting [250], FAP-targeting strategies show significant antitumor efficacy in preclinical models of lung, colon and pancreatic cancers (Fig. 3).